Lilly Asia Ventures has returned for the genomic drug developer's latest round, having already taken part in a $15m pre-series B round just over a year ago.
China-based genomic medicine developer EdiGene has raised approximately $11m in pre-series B2 funding from pharmaceutical firm Eli Lilly and venture capital group IDG Capital.
Eli Lilly provided the capital through Lilly Asia Ventures, the corporate venturing unit that led EdiGene’s $15m pre-series B round in August 2018. The 2018 round included IDG Capital, private equity firm Huagai Capital, VC firm WI Harper Group and unnamed existing shareholders.
Founded in 2015, EdiGene uses genome editing technologies to generate treatments for a…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
